FDA Expands TREMFYA Label, Cementing Its Lead in Psoriatic Arthritis
Event summary
- FDA approved a label expansion for Johnson & Johnson's TREMFYA (guselkumab) to include evidence of inhibiting structural joint damage in adults with active psoriatic arthritis (PsA).
- TREMFYA is now the only IL-23 inhibitor proven to stop further structural damage, positioning it as a first-line treatment option.
- The approval is supported by 24-week results from the Phase 3b APEX study, which met primary and major secondary endpoints.
- The study showed a 57% reduction in radiographic progression for patients who switched to TREMFYA from placebo.
The big picture
The FDA's label expansion for TREMFYA underscores the growing emphasis on early intervention in psoriatic arthritis to prevent irreversible joint damage. This strategic win for Johnson & Johnson comes as the IL-23 inhibitor class faces increasing competition, with rivals like AbbVie and Lilly pushing their own advancements. The approval not only solidifies TREMFYA's clinical profile but also positions it as a cornerstone in J&J's immunology portfolio, which generated over $10 billion in sales in 2025.
What we're watching
- Market Differentiation
- Whether TREMFYA's unique positioning as the only IL-23 inhibitor with structural inhibition in its label will drive market share gains against competitors like AbbVie's Skyrizi and Lilly's Omvoh.
- Clinical Efficacy
- The pace at which long-term data from the APEX study's extension phase will reinforce TREMFYA's durability in inhibiting joint damage and maintaining symptom control.
- Regulatory Strategy
- How Johnson & Johnson will leverage this approval to seek similar label expansions in other regions, potentially expanding TREMFYA's global reach.
Related topics